The Effect of Structural Violence on Patients with Sickle Cell Disease
Overview
Authors
Affiliations
Sickle Cell Disease (SCD) is a burdensome and prevalent condition predominantly seen in populations of African heritage. Treatments for SCD, particularly those related to pain crisis, are largely insufficient. We argue that it is through structural violence-a systemic series of policies, institutions, and practices-that individuals who live with SCD suffer from health disparities. Similarly, we argue against other suggested mechanisms and causes, such as purely economic factors or low public interest and knowledge. We shall do this in part by comparing the systemic response to SCD to that of Cystic Fibrosis (CF), another genetic based illness with similar prevalence. Notably, CF that affects a very different target population, and has very different research, funding, and treatment trajectories. Underlying these arguments is the hypothesis that structural violence can harm a population in a developed nation just as it can in a developing one.
Khan H, Guolian Kang , Porter J, Ding J, Wang W, Estepp J Blood Adv. 2024; 8(23):6088-6096.
PMID: 39373640 PMC: 11652775. DOI: 10.1182/bloodadvances.2023012379.
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.
Wesevich A, Peek M, Ratain M Ann Intern Med. 2023; 177(1):85-86.
PMID: 38048579 PMC: 11745142. DOI: 10.7326/M23-2428.
The Bias of Medicine in Sickle Cell Disease.
Anderson D, Lien K, Agwu C, Ang P, Abou Baker N J Gen Intern Med. 2023; 38(14):3247-3251.
PMID: 37698721 PMC: 10651605. DOI: 10.1007/s11606-023-08392-0.
Doorenbos A, Schlaeger J, deMartelly V, Burke L, Boyd A, Knisely M Contemp Clin Trials Commun. 2023; 32:101076.
PMID: 36852100 PMC: 9958255. DOI: 10.1016/j.conctc.2023.101076.
Blakey A, Lavarin C, Brochier A, Amaro C, Eilenberg J, Kavanagh P J Racial Ethn Health Disparities. 2022; 10(6):3095-3106.
PMID: 36536165 PMC: 10645630. DOI: 10.1007/s40615-022-01483-4.